In multivariate logistic regression analysis, hypoalbuminemia (OR 4.2, 95% CI: 1.6–11.2, p = 0.0039), autologous hematopoietic stem cell transplantation (AHSCT) before Rd (OR 2.6, 95% CI: 1.0–6.7, p = 0.048), and anemia grade ≥3 (OR 5.0, 95% CI: 1.8–14.0, p = 0.002) were independent factors related to the occurrence of infections. The overall response rate was 64.1%, 12.7% of patients achieved complete response, and 20.4% had a very good partial response. The median progression-free survival was 12.6 (95% CI: 9.5–16.2) months, and the median overall survival was 22.3 (95% CI: 15.9–28.6) months. The majority of patients (64.3%) received bortezomib-based regimens in the first line of treatment. Most patients (n = 110, 63.2%) received the Rd treatment in second-line treatment. The study group consisted of 174 patients and the median age was 65 years. A retrospective analysis of all patients who received the Rd regimen between 20 at our institution was performed. This study examines the clinical factors influencing the occurrence of infection in MM patients treated with lenalidomide and dexamethasone (Rd). However, they are associated with an increased risk of infectious complications. Lenalidomide-based regimens are effective treatment options for patients with relapsed/refractory multiple myeloma (RRMM).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2023
Categories |